Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.

Treatment-naïve BRVO eyes showed logMAR BCVA improvement (0.64 to 0.41) alongside CRT reduction (527 µm to 285 µm) over short-term follow-up with SB15. Central RVO eyes improved from logMAR 1.29 to 0.

An intravitreal ranibizumab injection was able to improve retinal sensitivity and thickness along with improving visual acuity. Branch retinal vein occlusion (BRVO) can affect people aged 40 years and ...

Patients with neovascular age‑related macular degeneration (AMD) whose retinal fluid cleared within 12 weeks of starting faricimab were more likely to have longer intervals between injections later in ...

Science has added a whole lot more cash to the bank, bringing in an impressive $230 million in its latest raise. | Science has added a whole lot more cash to the bank, bringing in an impressive $230 ...

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

Susvimo is an FDA-approved eye implant for diabetic macular edema that may reduce monthly injections to just two treatments a year while maintaining vision outcomes.

Researchers use single-cell analysis to show how transplanted neural stem cells interact with the retina to preserve vision in retinitis pigmentosa.